

Bartkowiak D, Thamm R, **Bottke D**, Siegmann A, Böhmer D, Budach V, Wiegel T:

Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.

Acta Oncol 2018; 57:362-367.

Bartkowiak D, **Bottke D**, Thamm R, Siegmann A, Hinkelbein W, Wiegel T:

The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.

Radiother Oncol 2016; 118:131-135.

Ebner F, Schramm A, **Bottke D**, Friedl TW, Wiegel T, Fink V, Lato K, Bekes I, Janni W, de Gregorio N:

Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost.

Arch Gynecol Obstet 2016; 294:861-866.

Wiegel T, Bartkowiak D, **Bottke D**, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhardt-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K:

Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.

Int J Radiat Oncol Biol Phys 2015; 91:288-294.

Witucki G, Degregorio N, Rempfen A, Schwentner L, **Bottke D**, Janni W, Ebner F:

Evaluation of Sentinel Lymph Node Dose Distribution in 3D Conformal Radiotherapy Techniques in 67 pN0 Breast Cancer Patients.

Int J Breast Cancer 2015; 2015:539842.

Lohm G, Lütcke J, Jamil B, Höcht S, Neumann K, Hinkelbein W, Wiegel T, **Bottke D**:

Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy – long-term follow-up of a single centre survey.

Strahlenther Onkol 2014; 190:727-731.

Wiegel T, Bartkowiak D, **Bottke D**, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhardt-Cabillic R, Hinke A, Hinkelbein W, Miller K:

Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

Eur Urol 2014; 66:243-250.

Bottke D, Golz R, Störkel S, Hinke A, Siegmann A, Hertle L, Miller K, Hinkelbein W, Wiegel T:

Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis.

Eur Urol 2013; 64:193-198.

Lohm G, **Bottke D**, Jamil B, Miller K, Neumann K, Bartkowiak D, Hinkelbein W, Wiegel T:

Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results.

World J Urol 2013; 31:423-428.

Bartkowiak D, Humble N, Suhr P, Hagg J, Mair K, Polivka B, Schneider U, **Bottke D**, Wiegel T:
Second cancer after radiotherapy, 1981-2007.
Radiother Oncol 2012; 105:122-126.

Siegmann A*, **Bottke D***, Faehndrich J, Brachert M, Lohm G, Miller K, Bartkowiak D, Hinkelbein W, Wiegel T:
Salvage radiotherapy after prostatectomy – What is the best time to treat?
Radiother Onkol 2012; 103:239-243.

**Both authors contributed equally to the manuscript*

Siegmann A*, **Bottke D***, Faehndrich J, Lohm G, Miller K, Bartkowiak D, Wiegel T, Hinkelbein W:
Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study.
Strahlenther Onkol 2011; 187:467-472.

**Both authors contributed equally to the manuscript*

Welte B, Suhr P, **Bottke D**, Bartkowiak D, Dörr W, Trott KR, Wiegel T:
Second malignancies in high-dose areas of previous tumor radiotherapy.
Strahlenther Onkol 2010; 186:174-179.

Bartkowiak D, Stempfhuber M, Wiegel T, **Bottke D**:
Radiation- and chemoinduced multidrug resistance in colon carcinoma cells.
Strahlenther Onkol 2009; 185:815-820.

Wiegel T, **Bottke D**, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rube C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K:
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
J Clin Oncol 2009; 27:2924-2930.

Wiegel T, Lohm G, **Bottke D**, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W:
Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Int J Radiat Oncol Biol Phys 2009; 73:1009-1016.

Bottke D, Koychev D, Busse A, Heufelder K, Wiegel T, Thiel E, Hinkelbein W, Keilholz U:
Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines.
Radiat Res 2008; 170:41-48.

Bottke D, Bathe K, Wiegel T, Hinkelbein W:
Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck.
Strahlenther Onkol 2007; 183:128-132.

Bottke D, Wiegel T, Kreusel KM, Höcht S, Hinkelbein W:
Is a diagnostic CT of the brain indicated in patients with choroidal metastases before radiotherapy?
Strahlenther Onkol 2005; 181:251-254.

Höcht S, Hammad R, Thiel HJ, Wiegel T, Siegmann A, Willner J, Wust P, Herrmann T, Eble M, Flentje M, Carstens D, **Bottke D**, Neumann P, Hinkelbein W:

Recurrent rectal cancer within the pelvis. A multicenter analysis of 123 patients and recommendations for adjuvant radiotherapy.

Strahlenther Onkol 2004; 180:15-20.

Schostak M, Wiegel T, Müller M, Hoecht S, Schrader M, Straub B, **Bottke D**, Hinkelbein W, Miller K:

Shared decision-making--results from an interdisciplinary consulting service for prostate cancer.

World J Urol 2004; 22:441-448.

Höcht S, Wiegel T, **Bottke D**, Jentsch H, Sternemann M, Rosenthal P, Hinkelbein W:

Computed tomogram prior to prostatectomy. Advantage in defining planning target volumes for postoperative adjuvant radiotherapy in patients with stage C prostate cancer?

Strahlenther Onkol 2002; 178:134-138.

Wiegel T, **Bottke D**, Bandlow P, Steiner U, Hinkelbein W:

The value of PSA measurements at 30 Gy, 50 Gy and 60 Gy for dose limitation in patients with radiotherapy for PSA increase after radical prostatectomy.

Strahlenther Onkol 2002; 178:422-425.

Wiegel T, **Bottke D**, Kreusel KM, Schmidt S, Bornfeld N, Foerster MH, Hinkelbein W; German Cancer Society:

External beam radiotherapy of choroidal metastases--final results of a prospective study of the German Cancer Society (ARO 95-08).

Radiother Oncol 2002; 64:13-18.

Bottke D, Wiegel T, Kreusel KM, Bornfeld N, Schaller G, Hinkelbein W:

Radiotherapy of choroidal metastases in patients with disseminated cancer.

Onkologie 2000; 23:572-575.

Wiegel T, Kreusel KM, Bornfeld N, **Bottke D**, Stange M, Foerster MH, Hinkelbein W:

Frequency of asymptomatic choroidal metastasis in patients with disseminated breast cancer: results of a prospective screening programme.

Br J Ophthalmol 1998; 82:1159-1161.

Bottke D, Bolenz C, Ott S, Cebulla A, Wiegel T:

Wann ist der Primärtumor eines Harnblasen- bzw. Prostatakarzinoms in der metastasierten Situation durch eine nicht-operative Maßnahme zu therapieren?

Urologe A 2017; 56:579-584.

Bottke D, Bartkowiak D, Bolenz C, Wiegel T:

Strahlentherapie beim nodal-positiven Prostatakarzinom.

Urologe A 2016; 55:345-349.

Bartkowiak D, **Bottke D**, Wiegel T:

Radiotherapy in the management of prostate cancer after radical prostatectomy.

Future Oncol 2013; 9:669-679

Bartkowiak D, **Bottke D**, Wiegel T:

Adjuvant radiotherapy or early salvage radiotherapy in pT3R0 or pT3R1 prostate cancer.

Curr Opin Urol 2013; 23:360-365

Bottke D, Scholz C, Bottke R, De Gregorio N, Janni W, Wiegel T:

Intraoperative Strahlentherapie beim Mammakarzinom. Evidenzbasierter Status.

Gynäkologe 2013; 46:581-584.

Bottke D, Bartkowiak D, Schrader M, Wiegel T:

Radiotherapy after radical prostatectomy: immediate or early delayed?

Strahlenther Onkol 2012;188:1096-1101.

Bottke D, Wiegel T:

Palliative strahlentherapeutische Konzepte bei Patienten mit Nierenzellkarzinom.

Onkologe 2010; 16:168-174.

Bottke D, Wiegel T:

Radiotherapy and prostate cancer: quo vadis?

Eur Urol Suppl 2010; 9:394-400.

Bottke D, Dourdoumas R, Wiegel T, Kreienberg R, Sauer G:

Intraoperative Strahlentherapie beim Mammakarzinom.

Gynäkologe 2009; 42:402-408.

Varga D, Rolle B, Sauer G, Wiegel T, Kreienberg R, **Bottke D**:

Endometriumkarzinom im Stadium IB: Stellenwert der Strahlentherapie gegenüber der Lymphadenektomie.

Gynäkologe 2009; 42:429-433.

Bottke D, de Reijke TM, Bartkowiak D, Wiegel T:

Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer.

Eur J Cancer 2009;45(Suppl 1):148-157.

Bottke D, Wiegel T:

pT3R1-Prostatakarzinom. Sofortige oder verzögerte Strahlentherapie nach radikaler Prostatektomie?

Urologe 2008;47:1431-1435.

Bottke D, Wiegel T:

Postoperative adjuvant radiotherapy – standard of care?
Front Radiat Ther Oncol 2008;41:32-38.

Bottke D, Abrahamsson PA, Welte B, Wiegel T:

Adjuvant radiotherapy after radical prostatectomy.
Eur J Cancer Suppl 2007;5:171-176.

Bottke D, Wiegel T:

Adjuvant radiotherapy after radical prostatectomy: indications, results and side effects.
Urol Int 2007;78:193-197.

Bottke D, Wiegel T:

Percutaneous radiotherapy for low-risk prostate cancer: options for 2007.
World J Urol 2007;25:53-57.

Bottke D, Wiegel T, Kreienberg R, Kurzeder C, Sauer G:

Stage IB endometrial cancer. Does lymphadenectomy replace adjuvant radiotherapy?
Strahlenther Onkol 2007;183:600-604.

Becker G, **Bottke D:**

Radiotherapy in the management of Kaposi's sarcoma.
Onkologie 2006;29:329-333.

Becker G, **Bottke D:**

Potential of radiation therapy in the multimodal management of Merkel cell carcinoma.
Front Radiat Ther Oncol 2006;39:87-95.

Bottke D, Wiegel T:

Vermeidung des Lokalrezidivs durch eine adjuvante Strahlentherapie nach radikaler Prostatektomie. Indikationen, Ergebnisse und Nebenwirkungen.
Urologe 2006;45:1251-1254.

Bottke D, Hammersen S, Höcht S, Hinkelbein W:

Spinales Kompressionssyndrom. Diagnostik und interdisziplinäre Therapie.
Onkologie 2004;10:345-350.

Bottke D, Wiegel T, Müller M, Höcht S, Altwein JE, Miller K, Hinkelbein W:

Strahlentherapie nach radikaler Prostatektomie. Vorgehen bei PSA-Anstieg oder -Persistenz ohne histologische Sicherung eines Lokalrezidivs.
Dtsch Arztebl 2004;101:A2255-2259.

Bottke D, Wiegel T, Höcht S, Müller M, Schostak M, Hinkelbein W:

Salvage radiotherapy in patients with persisting prostate-specific antigen after radical prostatectomy for prostate cancer.
Oncology 2003;65(Suppl1):18-23.

Bottke D, Bartkowiak D, Wiegel T:

Postoperative irradiation: immediate or early delayed?

In: Bolla M, van Poppel H (eds.): Management of Prostate Cancer. Springer International Publishing Switzerland, 2017, S. 231-250.

Bottke D, Wiegel T:

Randomized trials for adjuvant radiotherapy.

In: Geinitz H, Roach III M, van As N (eds.): Radiotherapy in Prostate Cancer: Innovative Techniques and Current Controversies. Springer-Verlag Berlin, 2015, S. 231-242.

Bottke D, Wiegel T:

Postoperative irradiation: immediate or early delayed?

In: Bolla M, van Poppel H (eds.): Management of Prostate Cancer. Springer-Verlag Berlin, Heidelberg, 2012, S. 173-189.

Bottke D, Gschwend JE, Wiegel T:

Niere und Harnleiter.

In: Bamberg M, Molls M, Sack H (eds.): Radioonkologie. Band 2: Klinik. W. Zuckschwerdt Verlag München, Wien, New York, 2009, S. 456-472.